• Willing and able to provide written informed consent for the trial.

• Be ≥ 21 years of age on the date of signing informed consent.

• ECOG performance status of 0 or 1.

• Histologically confirmed colorectal adenocarcinoma. Rectal cancers allowed if the treatment plan was upfront surgery with no need for any neoadjuvant chemotherapy or radiation.

• Clinical stage II (T3-4, N-) or stage III (Tany, N+).

• No evidence of distant metastases.

• Radiologically measurable or clinically evaluable disease.

• Negative pregnancy test done 72 hours before registration, for women of childbearing potential.

• Subjects of childbearing potential must be willing to use an adequate method of contraception. Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormone contraceptives, or double barrier method (diaphragm plus condom). Contraception, for the course of the study starting with the first dose of study medication through 150 days after the last dose of study medication. Note: abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.

• Non-childbearing potential is defined as follows:

⁃ ≥45 years of age and has not had a menstrual period for \>1 year

⁃ Patients who have been amenorrhoeic for \<2 years without a history of hysterectomy and oophorectomy must have a follicle-stimulating hormone value in the postmenopausal range upon screening evaluation

⁃ Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure; otherwise, the patient must be willing to use 2 adequate barrier methods throughout the study.

• Demonstrate adequate organ function as defined below, all screening labs should be performed within 28 days of treatment initiation.

∙ Haematological

⁃ Absolute neutrophil count (ANC) greater than or equal to 1,500/mcL.

• Platelets greater than or equal to 100,000/mcL.

• Haemoglobin greater than or equal to 9 g/dL.

‣ Renal

∙ · Serum creatinine OR Measured or calculated creatinine clearance (by Cockcroft-Gault equation), Serum creatinine less than or equal to 1.5 x upper limit of normal (ULN) OR creatinine clearance greater than or equal to 60 mL/min for subject with creatinine levels greater than 1.5 x ULN

‣ Hepatic

⁃ Serum total bilirubin less than or equal to 1.5 x ULN OR Direct bilirubin less than or equal to ULN for subjects with total bilirubin levels greater than 1.5 x ULN.

• AST and ALT less than or equal to 2.5 x ULN.

‣ Coagulation · International Normalised Ratio (INR) or Prothrombin Time (PT) or Activated Partial Thromboplastin Time (aPTT). For patients not taking warfarin: INR less than or equal to 1.5 or PT less than or equal to 1.5 x ULN; and either PTT or aPTT less than or equal to 1.5 x ULN. Patients on warfarin may be included on a stable dose with a therapeutic INR less than 3.5.